10-Q: Monogram Orthopaedics Reports Q1 2024 Results, Advances Towards 510(k) Submission

Monogram Orthopaedics reported a net loss of $3.5 million for Q1 2024, while making progress on its robotic surgical system and preparing for a 510(k) submission.

Summary

• Monogram Orthopaedics reported a net loss of $3,506,704 for the first quarter of 2024, compared to a net loss of $3,857,722 for the same period in 2023.
• The company's operating expenses totaled $3,610,159, a decrease from $3,895,065 in the first quarter of 2023, primarily due to a significant reduction in marketing and advertising expenses.
• Research and development expenses increased by 24.1% to $2,406,754, reflecting the company's move into the verification and validation phase of its robot prototype.
• The company had approximately $10.1 million in cash on hand as of March 31, 2024.
• Monogram is working towards a 510(k) submission for its mBs surgical system, with verification and validation testing expected to be largely complete in Q2 2024 and a submission anticipated in H2 2024.
• The company received positive feedback from the FDA regarding its pre-submission request and plans to conduct an outside-the-US clinical trial with approximately 100 knee surgeries at three sites with three months of follow-up.
• Monogram has a Common Stock Purchase Agreement with B. Riley Principal Capital, II LLC, allowing them to sell up to $20 million in shares, of which approximately $19.1 million remains available.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The company is making progress on its technology and regulatory pathway, but it is still operating at a loss and dependent on external funding. The positive FDA feedback and progress towards 510(k) submission are encouraging, but the financial risks remain significant.

Positives

• The net loss improved by 9.1% compared to the same quarter last year.
• Operating expenses decreased due to lower marketing costs.
• The company received positive feedback from the FDA, potentially streamlining the regulatory process.
• Monogram is progressing with its verification and validation testing, moving closer to a 510(k) submission.
• The company has a significant cash balance and access to additional capital through the B. Riley agreement.

Negatives

• The company continues to operate at a loss, with a net loss of $3.5 million for the quarter.
• Monogram has not yet generated any product revenue.
• The company is dependent on raising additional capital to continue operations.
• There is ongoing uncertainty regarding a potential payment to Mount Sinai related to a licensing agreement.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise capital and generate revenue.
• There is a risk of potential litigation with Mount Sinai over a licensing agreement payment.
• The company is subject to regulatory risks, including the need to obtain 510(k) clearance for its robotic products.
• The company is still in the development stage and has not yet achieved commercialization.
• The company may face challenges in establishing and maintaining supply relationships with third parties.

Future Outlook

The company anticipates completing verification and validation testing in Q2 2024 and submitting a 510(k) application in the second half of 2024. Monogram also plans to establish an ongoing OUS clinical strategy to support its innovation strategy.

Management Comments

• Management believes the FDA feedback was comprehensive and will be advantageous for preparing a successful 510(k) submission.
• Management assesses that the proposed testing plan generally appears acceptable to address the technical differences identified with the proposed predicate device.
• Management anticipates running an OUS clinical trial could save the Company significant cost and time.
• Management believes its current cash balances, plus the additional capital available under the Common Stock Purchase Agreement, will be sufficient for the Company to satisfy its near-term capital needs.

Industry Context

The company is operating in the growing market for robotic surgical systems, particularly in orthopaedics. Monogram is positioning itself with an active cutting robotic system that does not utilize haptic controls, which they believe differentiates them from competitors like Mako. The company is also focusing on personalized implants through 3D printing and robotics.

Comparison to Industry Standards

• Monogram is developing a robotic system for orthopaedic surgery, a market dominated by companies like Stryker with their Mako system.
• Unlike Mako, Monogram is focusing on an active cutting system without haptic controls, which they believe is a key differentiator.
• The company's focus on personalized implants through 3D printing aligns with a growing trend in the orthopaedic industry.
• Monogram's current financial results are typical for a pre-revenue medical device company, with significant R&D expenses and ongoing losses.
• The company's reliance on external funding is common in the medical device sector, particularly for companies developing complex technologies.

Corporate Governance

Legal Proceedings

• The company is currently in discussions with Mount Sinai regarding a potential payment obligation related to a licensing agreement.
• There is a risk of potential litigation if an agreement cannot be reached with Mount Sinai.

Stakeholder Impact

• Shareholders are impacted by the company's ongoing losses and the potential for dilution through future equity offerings.
• Employees are impacted by the company's financial performance and the need to achieve key milestones.
• Customers (surgeons and patients) are impacted by the company's progress in developing and commercializing its robotic surgical system.
• Suppliers are impacted by the company's ability to establish and maintain supply relationships.
• Creditors are impacted by the company's financial condition and its ability to meet its obligations.

Next Steps

• The company will complete verification and validation testing in Q2 2024.
• Monogram plans to submit a 510(k) application in the second half of 2024.
• The company will conduct an OUS clinical trial with approximately 100 knee surgeries.
• Monogram will continue to explore opportunities to raise additional capital.

Key Dates

Keywords

Orthopaedics, Robotics, Surgical System, 510(k) Clearance, Clinical Trial, Medical Device, 3D Printing, FDA, mBs TKA System, Monogram Orthopaedics